Jan 13 (Reuters) - Ocugen Inc :
* OCUGEN, INC. ANNOUNCES POSITIVE 2-YEAR DATA ACROSS MULTIPLE MUTATIONS FROM PHASE 1/2 CLINICAL TRIAL OF OCU400 —A NOVEL MODIFIER GENE THERAPY FOR RETINITIS PIGMENTOSA
* OCU400 SHOWS FAVORABLE LONG-TERM SAFETY AND TOLERABILITY
* PHASE 3 OCU400 TRIAL ON TARGET FOR BLA SUBMISSION IN 2026
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。